The RSNA Research and Education Foundation awards 93 grants from 47 institutions.
The Radiological Society of North America (RSNA) announced Tuesday that it has approved $4 million in research and educational grants.
Through the RSNA’s Research and Education (R&E) Foundation Board of Trustees, the group funded 28 percent of grant applications with awards going to radiologists at all stages of their careers.
“We are deeply grateful for the ongoing and generous support of our individual, practice group, and corporate donors who make supporting these researchers and educators possible,” said Thomas M. Grist, M.D., chair of the R&E Foundation Board of Trustees. “Because of the generosity of our donors, the RSNA R&E Foundation is able to support research and education efforts that elevate our specialty and place radiology at the forefront of innovation in medicine.”
All total, the Foundation approved grants to 93 recipients from 47 different institutions across North America. Of the group, 49 are new grant recipients, 26 are new medical student grants, and 18 are continuing grants.
The Foundation also launched an initiative this year to provide additional grants with medical students who identify as being from racial and ethnic groups who are underserved in medicine (UIM). This year’s UIM grants will fund students conducting research on optimizing immune responses for liver and skin cancer patients, as well as investigating how artificial intelligence can be used to classify bone lesions.
More information about the RSNA R&E Foundation and the funded 2020 projects can be found here.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.